232 related articles for article (PubMed ID: 35253798)
1. Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography.
Sakemura R; Cox MJ; Bansal A; Roman CM; Hefazi M; Vernon CJ; Glynn DL; Pandey MK; DeGrado TR; Siegler EL; Kenderian SS
J Vis Exp; 2022 Feb; (180):. PubMed ID: 35253798
[TBL] [Abstract][Full Text] [Related]
2. Spatiotemporal PET Imaging Reveals Differences in CAR-T Tumor Retention in Triple-Negative Breast Cancer Models.
Volpe A; Lang C; Lim L; Man F; Kurtys E; Ashmore-Harris C; Johnson P; Skourti E; de Rosales RTM; Fruhwirth GO
Mol Ther; 2020 Oct; 28(10):2271-2285. PubMed ID: 32645298
[TBL] [Abstract][Full Text] [Related]
3. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
Brudno JN; Maric I; Hartman SD; Rose JJ; Wang M; Lam N; Stetler-Stevenson M; Salem D; Yuan C; Pavletic S; Kanakry JA; Ali SA; Mikkilineni L; Feldman SA; Stroncek DF; Hansen BG; Lawrence J; Patel R; Hakim F; Gress RE; Kochenderfer JN
J Clin Oncol; 2018 Aug; 36(22):2267-2280. PubMed ID: 29812997
[TBL] [Abstract][Full Text] [Related]
4. Development of a Clinically Relevant Reporter for Chimeric Antigen Receptor T-cell Expansion, Trafficking, and Toxicity.
Sakemura R; Bansal A; Siegler EL; Hefazi M; Yang N; Khadka RH; Newsom AN; Hansen MJ; Cox MJ; Manriquez Roman C; Schick KJ; Can I; Tapper EE; Nevala WK; Adada MM; Bezerra ED; Kankeu Fonkoua LA; Horvei P; Ruff MW; Parikh SA; Pandey MK; DeGrado TR; Suksanpaisan L; Kay NE; Peng KW; Russell SJ; Kenderian SS
Cancer Immunol Res; 2021 Sep; 9(9):1035-1046. PubMed ID: 34244299
[TBL] [Abstract][Full Text] [Related]
5. PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors.
Murty S; Labanieh L; Murty T; Gowrishankar G; Haywood T; Alam IS; Beinat C; Robinson E; Aalipour A; Klysz DD; Cochran JR; Majzner RG; Mackall CL; Gambhir SS
Cancer Res; 2020 Nov; 80(21):4731-4740. PubMed ID: 32958548
[TBL] [Abstract][Full Text] [Related]
6. Clinical data, limitations and perspectives on chimeric antigen receptor T-cell therapy in multiple myeloma.
Beauvais D; Danhof S; Hayden PJ; Einsele H; Yakoub-Agha I
Curr Opin Oncol; 2020 Sep; 32(5):418-426. PubMed ID: 32740095
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
[TBL] [Abstract][Full Text] [Related]
8. Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art.
Abramson JS; Lunning M; Palomba ML
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():446-453. PubMed ID: 31099671
[TBL] [Abstract][Full Text] [Related]
9. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
10. Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.
Marofi F; Tahmasebi S; Rahman HS; Kaigorodov D; Markov A; Yumashev AV; Shomali N; Chartrand MS; Pathak Y; Mohammed RN; Jarahian M; Motavalli R; Motavalli Khiavi F
Stem Cell Res Ther; 2021 Mar; 12(1):217. PubMed ID: 33781320
[TBL] [Abstract][Full Text] [Related]
11. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity.
Yu S; Yi M; Qin S; Wu K
Mol Cancer; 2019 Aug; 18(1):125. PubMed ID: 31429760
[TBL] [Abstract][Full Text] [Related]
12. In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.
Ramos CA; Rouce R; Robertson CS; Reyna A; Narala N; Vyas G; Mehta B; Zhang H; Dakhova O; Carrum G; Kamble RT; Gee AP; Mei Z; Wu MF; Liu H; Grilley B; Rooney CM; Heslop HE; Brenner MK; Savoldo B; Dotti G
Mol Ther; 2018 Dec; 26(12):2727-2737. PubMed ID: 30309819
[TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
14. Molecular Imaging of Chimeric Antigen Receptor T Cells by ICOS-ImmunoPET.
Simonetta F; Alam IS; Lohmeyer JK; Sahaf B; Good Z; Chen W; Xiao Z; Hirai T; Scheller L; Engels P; Vermesh O; Robinson E; Haywood T; Sathirachinda A; Baker J; Malipatlolla MB; Schultz LM; Spiegel JY; Lee JT; Miklos DB; Mackall CL; Gambhir SS; Negrin RS
Clin Cancer Res; 2021 Feb; 27(4):1058-1068. PubMed ID: 33087332
[TBL] [Abstract][Full Text] [Related]
15. Chimeric antigen receptor T-cells: Properties, production, and quality control.
Ramesh P; Hui HYL; Brownrigg LM; Fuller KA; Erber WN
Int J Lab Hematol; 2023 Aug; 45(4):425-435. PubMed ID: 37337970
[TBL] [Abstract][Full Text] [Related]
16. Imaging CAR-NK cells targeted to HER2 ovarian cancer with human sodium-iodide symporter-based positron emission tomography.
Shalaby N; Xia Y; Kelly JJ; Sanchez-Pupo R; Martinez F; Fox MS; Thiessen JD; Hicks JW; Scholl TJ; Ronald JA
Eur J Nucl Med Mol Imaging; 2024 May; ():. PubMed ID: 38722382
[TBL] [Abstract][Full Text] [Related]
17. [Development of next-generation chimeric antigen receptor-engineered T-cell therapy].
Kagoya Y
Rinsho Ketsueki; 2022; 63(9):1290-1297. PubMed ID: 36198555
[TBL] [Abstract][Full Text] [Related]
18. CAR T cell therapy for multiple myeloma: where are we now and where are we headed?
Ghosh A; Mailankody S; Giralt SA; Landgren CO; Smith EL; Brentjens RJ
Leuk Lymphoma; 2018 Sep; 59(9):2056-2067. PubMed ID: 29105517
[TBL] [Abstract][Full Text] [Related]
19. CAR T-cell therapy against B-cell maturation antigen in multiple myeloma.
Cohen AD
Clin Adv Hematol Oncol; 2018 Dec; 16(12):804-806. PubMed ID: 30843888
[No Abstract] [Full Text] [Related]
20. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]